APLM
Apollomics Inc.Apollomics Inc. reported revenue of $0.00 in its most recent fiscal year. Figures below are compared against other companies classified under Pharmaceutical Preparations.
Grades vs. industry
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | Not reported | 68.6% | — |
Operating margin Operating income as a share of revenue. | Not reported | -31.8% | — |
Net margin Net income as a share of revenue. | Not reported | -30.0% | — |
Free cash flow margin Free cash flow as a share of revenue. | Not reported | -14.7% | — |
Return on equity Net income divided by shareholder equity. | -1107.3% | -49.7% | — |
Return on assets Net income divided by total assets. | -411.2% | -37.5% | 466 / 474 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | Not reported | -45.2% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | 0.00x | 0.25x | 1 / 133 |
Current ratio Current assets over current liabilities. | 1.39x | 3.99x | 395 / 472 |
Quick ratio Current assets excluding inventory, over current liabilities. | 1.39x | 3.62x | 382 / 472 |
Interest coverage Operating income divided by interest expense. | Not reported | -11.95x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -1.25x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Debt figures can be understated where a filer splits borrowings across XBRL tags this site does not match.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. 5 of the last 27 reported transactions were open-market purchases; the rest are mostly sales and compensation.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | LIN PETER KUAN-HOW Chief Financial Officer | Withheld for tax | 3,416 | $24.02 | $82.1K |
| Sep 15, 2026 | Chen Hung-Wen Chief Executive Officer | Option exercise(derivative) | 5,000 | $0.00 | $0.00 |
| Sep 15, 2026 | Yen Hung Hsien Director | Option exercise | 500 | $0.00 | $0.00 |
| Sep 15, 2026 | Yen Hung Hsien Director | Option exercise(derivative) | 500 | $0.00 | $0.00 |
| Sep 15, 2026 | TSAI HSIEN-SHU Director | Option exercise | 500 | $0.00 | $0.00 |
| Sep 15, 2026 | TSAI HSIEN-SHU Director | Option exercise(derivative) | 500 | $0.00 | $0.00 |
| Sep 15, 2026 | Chen Yi-Kuei Chief Operating Officer | Option exercise | 5,000 | $0.00 | $0.00 |
| Sep 15, 2026 | Chen Yi-Kuei Chief Operating Officer | Option exercise(derivative) | 5,000 | $0.00 | $0.00 |
| Sep 15, 2026 | CHEN HONG-JUNG Director | Option exercise | 500 | $0.00 | $0.00 |
| Sep 15, 2026 | CHEN HONG-JUNG Director | Option exercise(derivative) | 500 | $0.00 | $0.00 |
| Sep 15, 2026 | LIN PETER KUAN-HOW Chief Financial Officer | Option exercise | 10,000 | $0.00 | $0.00 |
| Sep 15, 2026 | Chen Hung-Wen Chief Executive Officer | Option exercise | 5,000 | $0.00 | $0.00 |
| Sep 15, 2026 | LIN PETER KUAN-HOW Chief Financial Officer | Option exercise(derivative) | 10,000 | $0.00 | $0.00 |
| Sep 14, 2026 | Chen Hung-Wen Chief Executive Officer | Grant or award(derivative) | 8,000 | $0.00 | $0.00 |
| Sep 14, 2026 | Huang Ya-Chi Director | Grant or award(derivative) | 2,000 | $0.00 | $0.00 |
| Sep 14, 2026 | Yen Hung Hsien Director | Grant or award(derivative) | 2,000 | $0.00 | $0.00 |
| Sep 14, 2026 | TSAI HSIEN-SHU Director | Grant or award(derivative) | 2,000 | $0.00 | $0.00 |
| Sep 14, 2026 | Chen Yi-Kuei Chief Operating Officer | Grant or award(derivative) | 8,000 | $0.00 | $0.00 |
| Sep 14, 2026 | CHEN HONG-JUNG Director | Grant or award(derivative) | 2,000 | $0.00 | $0.00 |
| Sep 14, 2026 | LIN PETER KUAN-HOW Chief Financial Officer | Grant or award(derivative) | 6,000 | $0.00 | $0.00 |
| Aug 17, 2026 | Huang Ya-Chi Director | Option exercise(derivative) | 500 | $0.00 | $0.00 |
| Aug 17, 2026 | Huang Ya-Chi Director | Option exercise | 500 | $0.00 | $0.00 |
| Aug 14, 2026 | Chen Hung-Wen Chief Executive Officer | Open-market purchase | 266,667 | $15.00 | $4.00M |
| Aug 14, 2026 | Chen Hung-Wen Chief Executive Officer | Open-market purchase | 166,667 | $12.00 | $2.00M |
| Aug 14, 2026 | Chen Hung-Wen Chief Executive Officer | Open-market purchase | 103,333 | $15.00 | $1.55M |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating income | — | — | $976.0K | — | — |
| Net income | -$53.86M | -$172.60M | -$240.81M | -$94.80M | -$74.82M |
| EPS (diluted) | -$52.80 | -$231.99 | n/c | n/c | n/c |
| Operating cash flow | -$28.74M | -$43.21M | -$42.82M | -$43.31M | -$35.68M |
| Capital expenditure | $24.0K | $6.0K | $367.0K | $50.0K | $144.0K |
| Free cash flow | -$28.77M | -$43.22M | -$43.19M | -$43.36M | -$35.83M |
| Total assets | $13.10M | $55.39M | $76.47M | $123.44M | — |
| Shareholder equity | $4.86M | $41.23M | -$448.12M | -$212.86M | -$127.93M |
| Total debt | $0.00 | $4.24M | — | — | — |
| Cash | $9.77M | $32.06M | $32.67M | $46.74M | $130.65M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
n/c marks per-share figures that are not comparable. Companies report each year as their filings stated it, and an annual report restates only its two prior years — so after a stock split, older years remain on the pre-split share count. Totals above are unaffected.
Source
Figures come from Apollomics Inc.’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 20-F filed Apr 3, 2025. View filings on EDGAR.